— Connect to Evaluate Efficacy and Safety Data on 255 Patients Already Enrolled —
— Expected Timing for Potential NDA Approval in China Remains Unchanged and is Targeted for 2025 —
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
— Connect to Evaluate Efficacy and Safety Data on 255 Patients Already Enrolled —
— Expected Timing for Potential NDA Approval in China Remains Unchanged and is Targeted for 2025 —
Read more at globenewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| CNTB | 2.36 | +0.05 | +2.16% |
| Connect Biopharma Holdings Ltd ADR | |||